Key Drivers
- Cash strength
- Margin pressure
- Rich valuation
AIAI Summary
Merck has shifted from a “safe defensive pharma” into a transition story where strong current cash flow and a reasonable valuation are being tested by the looming Keytruda patent cliff, so the key investment question is whether pipeline wins and new launches can clearly offset 2026+ erosion before sentiment turns decisively bearish.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash strength
- •Margin pressure
- •Rich valuation
Merck delivered strong full-year profitability and cash flow, but the latest quarter showed a sharp cost-driven earnings slump, slightly weaker liquidity, and a valuation that already assumes solid execution.
Price Behavior
Key Price Behavior Insights:
- •Failed Breakout
- •Support Holding
- •Sideways Consolidation
MRK remains in a mild downtrend over the last month, with sellers still in control after a late-April drop, but the stock is consolidating above $109–$111 and needs a reclaim of $114–$115 to improve momentum.
Sharp late-April drop followed by a partial rebound to $113.56 on 2026-05-06, then sideways trading
Sentiment & News
Key News Insights:
- •Keytruda growth
- •Raised EPS outlook
- •Technical breakdown
Merck beat Q1 estimates and raised EPS guidance on strong Keytruda sales, but LOE/patent-cliff concerns and a bearish chart signal keep the stock outlook mixed.
The news is fundamentally supportive for Merck, but near-term upside may be capped by patent-risk concerns and weaker technical momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings